Biologic Treatment of Pediatric Inflammatory Bowel Disease: A Decade of JPGN Contributions

Publication Year: 2014

Edition: 1st Ed.

Authors/Editor: Heyman, Melvin B.; Shamir, Raanan

Publisher: Lippincott Williams & Wilkins (LWW)

ISBN: 978-1-46-988716-6

Request Info

Description

This collection of articles from JPGN represent seminal work on the application, safety, and efficacy of the 2 leading anti-TNF agents, infliximab and adalimumab, to assist readers in considering treatment options and further advances in the care of pediatric patients with chronic IBD

Drug development in children and adolescents occasionally is hindered by a hesitance to expose young patients to experimental and untested therapies. A case in point is the application of biologic agents in the management of pediatric patients with inflammatory bowel disease (IBD). The degree of acceptance of antitumor necrosis factor (TNF) agents after their introduction as a novel treatment option has ranged from initial enthusiasm to caution resulting from fear of complications such as hepatosplenic T-cell lymphoma (HSTCL) to approval as part of standard management. In fact, as we gather additional experience and evidence, a trend toward the use of biologic agents as a first-line treatment has emerged.

Details

Platform: Ovid
Publisher: Lippincott Williams & Wilkins (LWW)
Product Type: Book
Author/Editor: Heyman, Melvin B.; Shamir, Raanan
ISBN: 978-1-46-988716-6
Specialty:
Internal Medicine
Pediatrics
Language: English
Edition: 1st Ed.
Pages: 148
Illustrations: 31
Year: 2014

Collections

Biologic Treatment of Pediatric Inflammatory Bowel Disease: A Decade of JPGN Contributions

Resources of the Month

Health & Psychosocial Instruments®

HAPI
 

Test Drive

Visible Body Heart & Circulatory Premium

Visible Body


Test Drive

Journal of Cataract and Refractive Surgery®

Academic Medicine


Test Drive

The Journal of Bone & Joint Surgery


Test Drive

Loading